
    
      One Russian center was approved for participation in this study. One center was initiated.
      Healthy volunteers were enrolled in 1 center. The study consisted of 4 periods: screening,
      single administration, multiple administration and follow-up.

      All eligible subjects were randomized into the study in appropriate cohort groups
      sequentially.

      Cohort 1 - XC8 or Placebo 2 mg once and then daily 14 days after a 6-day break; Cohort 2 -
      XC8 or Placebo 10 mg once and then daily during 14 days after a 6-day break; Cohort 3 - XC8
      or Placebo 50 mg once and then daily during 14 days after a 6-day break; Cohort 4 - XC8 or
      Placebo 200 mg once and then daily during 14 days after a 6-day break.

      The decision regarding increasing of the study drug dose for a subsequent cohort was made by
      the Data Safety Monitoring Committee on the basis of preliminary safety results assessment.

      A total of 20 volunteers received XC8 (2 mg, 10 mg, 50 mg or 200 mg) and a total of 8
      volunteers received the placebo during the study participation. The follow-up period lasted
      for 4 weeks.
    
  